Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 11/20 | 0.48 |
| ▸ | ACACA | Q13085 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23029670 | 1.00 | KLK7 (0.53) | KLK7ACACBL3MBTL1ACP1ACACA | |
| SCHEMBL23015346 | 0.90 | KLK7 (0.58) | KLK7L3MBTL1ACP1 | |
| SCHEMBL23029671 | 0.87 | KLK7 (0.51) | KLK7L3MBTL1ACP1 | |
| SCHEMBL23015387 | 0.83 | ACP1 (0.58) | ACP1 | |
| SCHEMBL29636780 | 0.83 | ACP1 (0.58) | ACP1 | |
| SCHEMBL23015255 | 0.83 | KLK7 (0.55) | KLK7L3MBTL1ACP1 | |
| SCHEMBL23015227 | 0.78 | ACP1 (0.56) | ACP1 | |
| SCHEMBL29908982 | 0.77 | DRD4 (0.42) | — | |
| SCHEMBL23015360 | 0.76 | ACP1 (0.61) | KLK7ACP1ACACA | |
| SCHEMBL29636654 | 0.76 | ACP1 (0.61) | KLK7ACP1ACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | claimed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |